Gastrointestinal bleeding with dabigatran, a comparative study with warfarin

a multicenter experience

Muhammed Sherid, Humberto Sifuentes, Samian Sulaiman, Salih Samo, Husein Husein, Ruth Tupper, Charles Spurr, Subbaramiah Sridhar

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

BACKGROUND/AIMS: The risk of gastrointestinal (GI) bleeding with dabigatran when compared to warfarin has been controversial in the literature. The aim of our study was to assess this risk with the use of dabigatran.

METHODS: We examined the medical records of patients who were started on dabigatran or warfarin from October 2010 to October 2012. The study was conducted in two hospitals.

RESULTS: A total of 417 patients were included (208 dabigatran vs. 209 warfarin). GI bleeding occurred in 10 patients (4.8%) in the dabigatran group compared to 21 patients (10.1%) in the warfarin group (p=0.0375). Multivariate analysis showed that patients who were on dabigatran for ≤ 100 days had a higher incidence of GI bleeding than those who were on it for >100 days (p=0.0007). The odds of GI bleeding in patients who were on dabigatran for ≤ 100 days was 8.2 times higher compared to those who were on the drug for >100 days. The incidence of GI bleeding in patients >65 years old was higher than in those <65 years old (p=0.0453, OR=3). History of previous GI bleeding was another risk factor for GI bleeding in the dabigatran group (p=0.036, OR=6.3). The lower GI tract was the most common site for GI bleeding in the dabigatran group (80.0% vs. 38.1%, p=0.014).

CONCLUSIONS: The risk of GI bleeding was lower with dabigatran. The risk factors for GI bleeding with dabigatran were the first 100 days, age >65 years, and a history of previous GI bleeding.

Original languageEnglish (US)
Pages (from-to)205-214
Number of pages10
JournalThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Volume65
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Warfarin
Hemorrhage
Incidence
Dabigatran
Medical Records
Multivariate Analysis
Pharmaceutical Preparations

Keywords

  • Antithrombins
  • Dabigatran
  • Gastrointestinal hemorrhage
  • Platelet aggregation inhibitors
  • Warfarin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gastrointestinal bleeding with dabigatran, a comparative study with warfarin : a multicenter experience. / Sherid, Muhammed; Sifuentes, Humberto; Sulaiman, Samian; Samo, Salih; Husein, Husein; Tupper, Ruth; Spurr, Charles; Sridhar, Subbaramiah.

In: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, Vol. 65, No. 4, 01.04.2015, p. 205-214.

Research output: Contribution to journalArticle

Sherid, Muhammed ; Sifuentes, Humberto ; Sulaiman, Samian ; Samo, Salih ; Husein, Husein ; Tupper, Ruth ; Spurr, Charles ; Sridhar, Subbaramiah. / Gastrointestinal bleeding with dabigatran, a comparative study with warfarin : a multicenter experience. In: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi. 2015 ; Vol. 65, No. 4. pp. 205-214.
@article{a2be445fa8804e488125bae194987bec,
title = "Gastrointestinal bleeding with dabigatran, a comparative study with warfarin: a multicenter experience",
abstract = "BACKGROUND/AIMS: The risk of gastrointestinal (GI) bleeding with dabigatran when compared to warfarin has been controversial in the literature. The aim of our study was to assess this risk with the use of dabigatran.METHODS: We examined the medical records of patients who were started on dabigatran or warfarin from October 2010 to October 2012. The study was conducted in two hospitals.RESULTS: A total of 417 patients were included (208 dabigatran vs. 209 warfarin). GI bleeding occurred in 10 patients (4.8{\%}) in the dabigatran group compared to 21 patients (10.1{\%}) in the warfarin group (p=0.0375). Multivariate analysis showed that patients who were on dabigatran for ≤ 100 days had a higher incidence of GI bleeding than those who were on it for >100 days (p=0.0007). The odds of GI bleeding in patients who were on dabigatran for ≤ 100 days was 8.2 times higher compared to those who were on the drug for >100 days. The incidence of GI bleeding in patients >65 years old was higher than in those <65 years old (p=0.0453, OR=3). History of previous GI bleeding was another risk factor for GI bleeding in the dabigatran group (p=0.036, OR=6.3). The lower GI tract was the most common site for GI bleeding in the dabigatran group (80.0{\%} vs. 38.1{\%}, p=0.014).CONCLUSIONS: The risk of GI bleeding was lower with dabigatran. The risk factors for GI bleeding with dabigatran were the first 100 days, age >65 years, and a history of previous GI bleeding.",
keywords = "Antithrombins, Dabigatran, Gastrointestinal hemorrhage, Platelet aggregation inhibitors, Warfarin",
author = "Muhammed Sherid and Humberto Sifuentes and Samian Sulaiman and Salih Samo and Husein Husein and Ruth Tupper and Charles Spurr and Subbaramiah Sridhar",
year = "2015",
month = "4",
day = "1",
doi = "10.4166/kjg.2015.65.4.205",
language = "English (US)",
volume = "65",
pages = "205--214",
journal = "The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi",
issn = "1598-9992",
publisher = "Korean Society of Gastroenterology",
number = "4",

}

TY - JOUR

T1 - Gastrointestinal bleeding with dabigatran, a comparative study with warfarin

T2 - a multicenter experience

AU - Sherid, Muhammed

AU - Sifuentes, Humberto

AU - Sulaiman, Samian

AU - Samo, Salih

AU - Husein, Husein

AU - Tupper, Ruth

AU - Spurr, Charles

AU - Sridhar, Subbaramiah

PY - 2015/4/1

Y1 - 2015/4/1

N2 - BACKGROUND/AIMS: The risk of gastrointestinal (GI) bleeding with dabigatran when compared to warfarin has been controversial in the literature. The aim of our study was to assess this risk with the use of dabigatran.METHODS: We examined the medical records of patients who were started on dabigatran or warfarin from October 2010 to October 2012. The study was conducted in two hospitals.RESULTS: A total of 417 patients were included (208 dabigatran vs. 209 warfarin). GI bleeding occurred in 10 patients (4.8%) in the dabigatran group compared to 21 patients (10.1%) in the warfarin group (p=0.0375). Multivariate analysis showed that patients who were on dabigatran for ≤ 100 days had a higher incidence of GI bleeding than those who were on it for >100 days (p=0.0007). The odds of GI bleeding in patients who were on dabigatran for ≤ 100 days was 8.2 times higher compared to those who were on the drug for >100 days. The incidence of GI bleeding in patients >65 years old was higher than in those <65 years old (p=0.0453, OR=3). History of previous GI bleeding was another risk factor for GI bleeding in the dabigatran group (p=0.036, OR=6.3). The lower GI tract was the most common site for GI bleeding in the dabigatran group (80.0% vs. 38.1%, p=0.014).CONCLUSIONS: The risk of GI bleeding was lower with dabigatran. The risk factors for GI bleeding with dabigatran were the first 100 days, age >65 years, and a history of previous GI bleeding.

AB - BACKGROUND/AIMS: The risk of gastrointestinal (GI) bleeding with dabigatran when compared to warfarin has been controversial in the literature. The aim of our study was to assess this risk with the use of dabigatran.METHODS: We examined the medical records of patients who were started on dabigatran or warfarin from October 2010 to October 2012. The study was conducted in two hospitals.RESULTS: A total of 417 patients were included (208 dabigatran vs. 209 warfarin). GI bleeding occurred in 10 patients (4.8%) in the dabigatran group compared to 21 patients (10.1%) in the warfarin group (p=0.0375). Multivariate analysis showed that patients who were on dabigatran for ≤ 100 days had a higher incidence of GI bleeding than those who were on it for >100 days (p=0.0007). The odds of GI bleeding in patients who were on dabigatran for ≤ 100 days was 8.2 times higher compared to those who were on the drug for >100 days. The incidence of GI bleeding in patients >65 years old was higher than in those <65 years old (p=0.0453, OR=3). History of previous GI bleeding was another risk factor for GI bleeding in the dabigatran group (p=0.036, OR=6.3). The lower GI tract was the most common site for GI bleeding in the dabigatran group (80.0% vs. 38.1%, p=0.014).CONCLUSIONS: The risk of GI bleeding was lower with dabigatran. The risk factors for GI bleeding with dabigatran were the first 100 days, age >65 years, and a history of previous GI bleeding.

KW - Antithrombins

KW - Dabigatran

KW - Gastrointestinal hemorrhage

KW - Platelet aggregation inhibitors

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=85015349362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015349362&partnerID=8YFLogxK

U2 - 10.4166/kjg.2015.65.4.205

DO - 10.4166/kjg.2015.65.4.205

M3 - Article

VL - 65

SP - 205

EP - 214

JO - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

JF - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

SN - 1598-9992

IS - 4

ER -